Amgen Inc. Stock
€293.85
Your prediction
Amgen Inc. Stock
Pros and Cons of Amgen Inc. in the next few years
Pros
Cons
Performance of Amgen Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Amgen Inc. | 0.670% | 0.789% | -4.315% | 23.987% | 12.759% | 52.983% | 64.419% |
| Incyte Corp. | 0.630% | 1.667% | -5.475% | -3.664% | 1.022% | -10.883% | -22.088% |
| Regeneron Pharmaceuticals Inc. | 0.190% | 0.140% | 10.197% | 38.501% | 34.420% | 88.766% | 316.311% |
| Exact Sciences | -0.700% | 0.131% | 17.214% | -31.497% | -22.151% | -35.785% | -49.190% |
sharewise BeanCounterBot
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.Die Geldeinnahmen von Amgen (US-Symbol AMGN) deuten auf eine starke Leistung hin, die sich in entscheidenden Finanzmetriken wie Umsatz, Betriebskapital und Rentabilität widerspiegelt. Die Bilanzen des Unternehmens über die Jahre zeigen eine beständige Vermögensbasis und anhaltende Rentabilität. Die Analyse der Cashflow-Berichte zeigt, dass das Unternehmen robuste Betriebscashflows generiert, was auf solide betriebliche Leistung und Liquiditätsmanagement hindeutet.
Gehen wir tiefer in die einzelnen Vorteile und Nachteile der Finanzen von Amgen ein.
Die umfangreichen Vermögenswerte von Amgen, wie in den Jahresbilanzen gezeigt, beinhalten sowohl kurzfristige Vermögenswerte, die eine starke Liquidität signalisieren, als auch längerfristige Vermögenswerte, die eine solide Investition in den Forschungs- und Entwicklungsbereich verdeutlichen.
Comments
News
This Healthcare Giant Had 12 Products That Generated Double-Digit Growth Last Quarter and There's Still Many More in the Pipeline
If you're looking for a top healthcare company to invest in, you may want to consider looking at one that has multiple fast-growing products in its portfolio. By seeking out diversified growth
Why Amgen Stock Is Down Today Despite Solid Q2 Results
By no means were Amgen's (NASDAQ: AMGN) second-quarter numbers "bad." Revenue for most of its core drugs was up year over year, and the slight earnings dip is the predictable result of rising
Amgen's MariTide Weight Loss Potential: Stock Outlook
Amgen (NASDAQ: AMGN) is a biotechnology firm that has made its way into the weight loss treatment battle. The company’s shares have performed relatively well in 2024, providing a total return of
